Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
2017; Elsevier BV; Volume: 131; Issue: 8 Linguagem: Inglês
10.1182/blood-2017-08-802470
ISSN1528-0020
AutoresSteven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison J. Moskowitz, Megan N. Perez, Patricia L. Myskowski, Adam Officer, Jacob D. Jaffe, Sara Morrow, Kerstin Allen, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David T. Weaver, Francine M. Foss, David M. Weinstock,
Tópico(s)Cutaneous lymphoproliferative disorders research
ResumoKey Points The oral PI3K-δ,γ inhibitor duvelisib demonstrated clinical activity and a favorable safety profile in patients with CTCL and PTCL. Duvelisib induced cell-autonomous killing of TCL lines and reprogrammed PTCL-associated macrophages in vivo.
Referência(s)